EPISODE · Mar 23, 2021 · 37 MIN
Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix
from Mendelspod Podcast · host Theral Timpson
Kevin Hrusovosky’s career has been dedicated to transforming medicine from reactive “sick care” to preventative personalized care. A serial entrepreneur, he currently serves as the CEO of Quanterix, a company which has just nabbed $700 million and is raising the bar on proteomics testing.“Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.” This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
NOW PLAYING
Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m